Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...
Zacks.com on MSN14h
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With TevaShares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback